“New 5-HT2B Partial Agonist, VU6047534, Shows Promise in Preventing and Treating Pulmonary Arterial Hypertension in Preclinical Models”

https://pubmed.ncbi.nlm.nih.gov/38094686

A newly developed, peripherally restricted 5-HT2B partial agonist called VU6047534 shows potential for preventing and treating pulmonary arterial hypertension in preclinical models.